

PVR INOX | BUY

Over the OTT hump?

PVR Inox's 1Q revenue growth (+23% YoY) was marginally ahead of JMFe: 20%. Underlying construct of their performance was far more encouraging though. Box office collection (BOC), up 21% YoY, was well distributed across language, genres and movie budgets. 10 movies crossed INR 1bn BOC in 1Q (None above INR 5bn). As we argued in [An encore](#), 24 Aug 2023, skewness of BOC towards a few mega hits alongside a longer tail of flops is a possible impact of OTT. Conversely, equitable performance implies that OTT impact is waning. Sleeper hits such as "Tourist Family" are evidence that viewers are willing to visit Cinemas even for low budget movies apt for OTT viewing. That then restricts the reason for poor BOC of recent quarters to inconsistent content flow. That has already reversed. Q2 is off to a good start. Content pipeline for Q2/Q3 is looking even better. That is informing management's confidence of exceeding FY24's record admits (151mn) in FY26. 8%/11% higher ATP/SPH in FY26E (JMFe) and lower fixed cost mean revenue/EBITDA could be much higher. That coupled with 10x EV/EBITDA (pre Ind AS) – 1-SD below 10 year mean – make current levels attractive to play the seasonal and, hopefully, structural uptick. BUY.

- **1QFY26 – beats expectations:** PVR Inox reported revenues of INR 14.7bn (23.4% YoY / 17.5% QoQ), beating JMFe (INR 14.3bn). Growth was broad-based across segments. Ticketing/F&B revenues grew 22.7%/22.4% YoY. Advertisement revenue grew 17% YoY to highest since pandemic. Other operating income (Movie distribution) grew 57% YoY led by movies such as Raid 2, Sitaare Zameen Par and Ballerina. Adjusted EBITDA (pre Ind-AS) came in at INR 953 Mn, in-line with JMFe (INR 971 Mn). PAT came in at -INR 545 Mn (vs JMFe: INR -341 Mn). PAT loss reduced considerably compared to 1QFY25 (INR -1,787 Mn). Net debt reduced further by INR 607mn (6.4%) sequentially to INR 8.9 bn.
- **Operational metrics:** PVR's GBOC grew 21%/10% YoY/QoQ to INR 8.6 bn. This was led by Hollywood (+72% YoY) and Bollywood (38% YoY) even as regional GBOC was stable (-4.2%). 10 films crossed INR 1bn (India GBOC) mark in the quarter with 3 crossing the INR 2bn mark. Admits in 1Q grew 11.8% YoY (11.5% QoQ) to 34.0mn. Footfall initiatives such as 'Blockbuster Tuesdays' (1mn admits), re-releases and live events (0.5mn admits) were successful in drawing admits. Occupancy at 22.0% was in-line with JMFe. ATP/SPH increased 8.1%/10.4% YoY (-1.6%/18% QoQ) driven by favourable mix drawing higher spending audience. PVR has signed 55/72 new screens under FOCO/Asset light model which are set to open in FY26-27. 20 screens were added in 1Q and 90-100 new screens are planned for FY26.
- **Outlook- Promising line-up:** PVR expects strong footfalls and occupancy in the coming quarters, supported by a pipeline that includes War2, Coolie, and Jolly LLB in Bollywood and Avatar and Conjuring in Hollywood. Q2 performance to date has been robust, aided by the success of Saiyaara, Superman and Jurassic. Management expressed confidence that FY26 occupancies and admits will surpass FY24 levels (151mn admits). Our FY26-28E EPS is up 3-4%, though confidence on these estimates are higher now. Our DCF based TP is broadly unchanged at INR 1,380. At 10x EV/EBITDA, valuations are attractive. BUY.

Financial Summary					(INR mn)
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Sales	60,540	57,221	69,216	75,576	77,986
Sales Growth (%)	67.7	-5.8	21.0	9.2	3.2
EBITDA*	7,121	3,756	8,856	10,589	10,704
EBITDA Margin (%)	11.7	6.5	12.7	13.9	13.3
Adjusted Net Profit	-320	-2,794	2,768	4,092	5,142
Diluted EPS (INR)	-3.3	-28.7	28.4	42.0	52.8
Diluted EPS Growth (%)	0.0	0.0	0.0	47.8	25.7
ROIC (%)	5.1	2.4	9.1	12.2	13.2
ROE (%)	-0.4	-3.9	3.9	5.4	6.5
P/E (x)	-315.4	-36.1	36.5	24.7	19.6
P/B (x)	1.4	1.4	1.4	1.3	1.2
EV/EBITDA (x)	16.0	29.5	12.0	9.6	9.2
Dividend Yield (%)	0.0	0.0	0.4	0.7	1.0

Note: *Pre-Ind AS EBITDA. Source: Company data, JM Financial. Note: Valuations as of 06/Aug/2025



Abhishek Kumar

abhishek.kumar@jmfl.com | Tel: (91 22) 66303053

Nandan Arekal

nandan.arekal@jmfl.com | Tel: (91 22) 62243683

Anushree Rustagi

anushree.rustagi@jmfl.com | Tel: (91 22) 69703668

Recommendation and Price Target

Current Reco.	BUY
Previous Reco.	BUY
Current Price Target (12M)	1,380
Upside/(Downside)	33.3%
Previous Price Target	1,390
Change	-0.7%

Key Data – PVRINOX IN

Current Market Price	INR1,036
Market cap (bn)	INR101.7/US\$1.2
Free Float	88%
Shares in issue (mn)	98.0
Diluted share (mn)	97.4
3-mon avg daily val (mn)	INR353.9/US\$4.0
52-week range	1,748/826
Sensex/Nifty	80,544/24,574
INR/US\$	87.7

Price Performance

%	1M	6M	12M
Absolute	6.0	-7.7	-26.4
Relative*	9.8	-10.7	-27.3

* To the BSE Sensex

JM Financial Research is also available on:
Bloomberg - JMFR <GO>,
Thomson Publisher & Reuters,
S&P Capital IQ, FactSet and Visible Alpha

Please see Appendix I at the end of this report for Important Disclosures and Disclaimers and Research Analyst Certification.

1QFY26 result review

Exhibit 1. Key Financials

	4Q24	FY24	1Q25	2Q25	3Q25	4Q25	FY25	1Q26
Sale of movie tickets	6,353	32,799	5,935	8,376	8,791	6,447	29,549	7,281
Foods & Beverages	4,132	19,584	4,018	5,232	5,209	3,811	18,270	4,919
Advertisement	1,045	4,519	934	1,093	1,486	962	4,475	1,096
Others	437	2,181	438	650	581	442	2,111	481
Revenue (INR mn)	12,564	61,071	11,907	16,221	17,173	12,498	57,799	14,691
Film exhibition cost	2,469	14,113	2,451	3,257	3,549	2,523	11,780	2,804
Cost of F&B	1,131	4,994	1,005	1,330	1,340	999	4,674	1,196
Gross Profit	8,964	41,964	8,451	11,634	12,284	8,976	41,345	10,691
Staff Cost	1,706	6,573	1,643	1,773	1,740	1,704	6,860	1,726
Other Expenditure	4,474	17,290	4,293	5,068	5,267	4,441	19,069	4,992
EBITDA	2,784	18,101	2,515	4,793	5,277	2,831	15,416	3,973
- Margin	22.2%	29.6%	21.1%	29.5%	30.7%	22.7%	26.7%	27.0%
Pre IND AS 116 EBITDA	12	7,121	-378	1,871	2,368	-105	3,756	953
- Margin	0.1%	11.7%	-3.2%	11.5%	13.8%	-0.8%	6.5%	6.5%
PAT	-1,295	-320	-1,787	-118	359	-1,250	-2,796	-540
EPS	-13.2	-3.3	-18.2	-1.2	3.7	-12.7	-28.4	-5.5

Source: Company, JM Financial

Exhibit 2. 1QFY26 Result Summary


INR mn	1QFY26A	4QFY25A	QoQ	1QFY25A	YoY	JMFe	Vs JMFe
Key Financials							
Consol. Revenue	14,691	12,498	17.5%	11,907	23.4%	14,258	3.0%
Reported EBITDA	3,973	2,831	40.3%	2,515	58.0%	3,919	1.4%
- margin	27.0%	22.7%	439 bps	21%	592 bps	27.5%	-44 bps
Adjusted EBITDA	953	-105	1007.6%	-378	-352.1%	971	-1.8%
- margin	6.5%	-0.8%	733 bps	-3.2%	966 bps	6.8%	-32 bps
PAT	-545	-1,250	56.4%	-1,787	-69.5%	-341	60.0%
EPS	-5.5	-12.8	57.0%	-18.2	-69.8%	-3.5	57.5%
Operating Metrics - Ticketing							
Screens	1743	1,723	1.2%	1,754	-0.6%	1,743	0.0%
Admits (Mn)	34.0	30.5	11.5%	30.4	11.8%	33.64	1.1%
Occupancy	22.0%	20.5%	150 bps	20.3%	170 bps	22.5%	-50 bps
ATP (INR)	254	258	-1.6%	235	8.1%	249	2.1%
Income from ticketing	7,281	6,447	12.9%	5,935	22.7%	7,094	2.6%
Operating Metrics - F&B							
SPH (INR)	148	125	18.4%	134	10.4%	143	3.7%
Income from F&B	4,919	3,811	29.1%	4,018	22.4%	4,803	2.4%

Source: Company, JM Financial estimates

Key Highlights from the call


- **Demand:** Management highlighted that overall operating metrics improved YoY in Q1FY26, with admissions rising 12% to 34mn despite the external macro disruptions, which collectively led to a loss of ~0.6-0.7mn admissions. Leadership noted that ATP grew 8% YoY to INR 254, while spend per head on F&B reached INR 148, marking a 10% YoY increase and the highest on record. The quarter also witnessed highest since the pandemic advertising revenue. Leadership highlighted that footfalls were aided by value-driven initiatives such as the INR 99 Tuesday offer, aimed at widening weekday occupancy among students, homemakers, and senior citizens.
- **Outlook:** Management remains optimistic on the theatrical momentum for FY26, supported by a strong release slate across Hindi, regional, and Hollywood segments. They noted that key upcoming titles include War 2, Coolie, Jolly LLB 3, Love & War, and Toxic, among others. Leadership highlighted that July has already seen record admissions over the last 18 months, with strong performance across languages. Management expects this momentum to sustain in H2, aided by better content visibility, higher operating leverage, and favorable seasonality in Q2 and Q3, with Q3 historically being the strongest quarter in a fiscal.
- **Content performance:** Management attributed the broad-based box office recovery in Q1FY26 to a combination of factors including stronger content quality, reduced OTT stickiness, and improved audience connect. Ten films crossed INR 1bn in collections during the quarter, with performance distributed across Hindi, regional, and Hollywood titles. Leadership pointed to growing OTT fatigue and noted that recent releases are resonating due to sharper storytelling, higher production values, and a clear shift from star-driven to story-driven narratives. Additionally, they highlighted that creators are increasingly designing films with pan-India appeal, expanding audience reach across languages and formats.
- **Capex plans:** Management reiterated its guidance for FY26 capex at INR 4-4.25bn, comprising INR 2.5-2.6bn for new screens, INR 700-750mn for renovations, and the balance for maintenance and IT upgrades. While 20 screens were added during Q1, management confirmed the overall screen rollout for the year remains on track, with an increasing tilt towards low-capex formats. They mentioned that no screens were closed during the quarter, and the company continues to maintain a disciplined capital allocation approach aimed at enhancing cash flow generation.
- **Asset light strategy:** Of the 20 screens opened in Q1, management noted that 14 were under FOCO and asset-light formats. They highlighted that an additional 127 screens have already been signed and are expected to go live over the next 18-24 months. Management emphasized that margins on these formats remain healthy, and RoCE improves meaningfully due to lower upfront investments. They noted that FOCO arrangements allow full EBITDA flow-through via management fees, while joint-investment models with developers improve breakeven timelines and scalability.
- **Margins:** Q1FY26 adj. EBITDA margin witnessed a 730bps sequential expansion on the back of 150bps occupancy expansion. Management noted that margin improvement was primarily driven by strong cost controls across electricity, staffing, and resource utilization, as the share of asset-light formats remains low at present. Management clarified that recent efficiency gains were the result of post-merger scale benefits and operating discipline, rather than from mix shift.
- **Footfall initiatives:** Management continued its focus on “manufacturing footfalls” through targeted weekday promotions and bundled F&B offers. They noted that Blockbuster Tuesday, featuring INR 99 tickets, was a key lever in driving incremental footfalls from underpenetrated weekday segments such as students, housewives, and senior citizens. Additionally, they highlighted that complementary offers like unlimited refill promotions helped improve F&B conversion, with management reporting that 50-60% of growth in spend per head was driven by volume rather than pricing.

Exhibit 1. Admits and Occupancy trends



Source: Company, JM Financial

Exhibit 2. ATP & SPH trends




Source: Company, JM Financial

Exhibit 3. Revenue trends




Source: Company, JM Financial

Exhibit 4. Revenue mix




Source: Company, JM Financial

Exhibit 5. EBITDA and EBITDA margin trend



Source: Company, JM Financial

Exhibit 6. EBITDA – pre IND AS116 and EBITDA margin trend



Source: Company, JM Financial

Maintain BUY, TP Revised to INR 1,380.

PVR-INOX reported a strong set of numbers in 1Q. We have raised our revenue and PAT estimates but our EBITDA estimates have been lowered. Our consol. revenue estimates have been increased by 2.8%-5.7% over FY26-28E. This is driven by 2.8%-3.3% increase in ticketing revenue, 2.7%-3.7% increase in F&B and 5.5%-35% increase in other operating income over the same period. Estimates for Admits have seen an increase while ATP and SPH assumptions remain unchanged.

We have lowered our Pre-Ind AS EBITDA margins by 180bps – 220 bps over FY26-28E. This is due to an increase of 365bps-390 bps (% of Rev.) in other expenditure, which includes movie distribution/print costs. Gross margins and staff costs see limited changes. Despite the EBITDA downgrade, PAT estimates have been raised by 3%-4% over FY26-28E, aided by lower depreciation assumptions. Our DCF based TP is lowered on account of increases to our tax and working capital assumptions. TP is revised to INR 1,380 from INR 1,390 earlier. We maintain a BUY rating.

Exhibit 7. What has Changed

	Old			New			Change		
	FY26	FY27	FY28	FY26	FY27	FY28	FY26	FY27	FY28
Sale of tickets	35,068	38,414	38,723	36,048	39,284	40,011	2.8%	2.3%	3.3%
Sale of food and beverages	21,336	23,858	24,551	21,921	24,460	25,448	2.7%	2.5%	3.7%
Income from advertisement	5,270	5,826	6,352	5,272	5,828	6,295	0.0%	0.0%	-0.9%
Other	6,305	6,119	6,265	6,652	6,723	8,459	5.5%	9.9%	35.0%
Consol Revenue	67,979	74,217	75,892	69,893	76,295	80,212	2.8%	2.8%	5.7%
Gross Profit	47,312	51,496	53,086	50,015	54,222	56,816	5.7%	5.3%	7.0%
Gross Profit margin	70%	69%	70%	72%	71%	71%	196bp	168bp	88bp
EBITDA	21,730	24,468	25,202	21,302	23,607	24,584	-2.0%	-3.5%	-2.5%
EBITDA margin	32.0%	33.0%	33.2%	30.5%	30.9%	30.6%	-149bp	-203bp	-256bp
Pre Ind As EBITDA	9,833	11,912	11,791	8,856	10,589	10,704	-9.9%	-11.1%	-9.2%
Pre Ind As EBITDA margin	14.5%	16.1%	15.5%	12.7%	13.9%	13.3%	-179bp	-217bp	-219bp
PAT	2,679	3,969	4,935	2,768	4,092	5,142	3.3%	3.1%	4.2%
EPS	28	41	51	28	42	53	3.3%	3.1%	4.2%
No. of Screens	1,723	1,808	1,858	1,723	1,808	1,858	0.0%	0.0%	0.0%
Admits (Mn)	137	149	155	137	152	158	0.0%	2.4%	1.9%
Occupancy	23.0%	24.5%	24.5%	23.0%	24.4%	24.3%	0bp	-13bp	-25bp
Average Ticket realisation	216	236	247	216	236	248	0.0%	0.4%	0.4%
Income from sale of movie tickets	29,549	35,068	38,414	29,549	36,048	39,284	0.0%	2.8%	2.3%
Gross spend per head	133	143	154	133	144	155	0.0%	0.3%	0.6%

Source: JM Financial estimates

Exhibit 8. 12M Fwd. intrinsic EV/EBITDA at close to -1SD levels


EV/EBITDA (Pre-INDAS) 12M Fwd – 10 year chart



Source: JM Financial, Bloomberg


Q1FY26 Capabilities and Performance

Exhibit 9. Diversified screen network of 1,745 screens across India



Source: Company, JM Financial


Exhibit 10. Sequential and YoY growth in BO collections



Robust performance across all key parameters with Highest ever SPH

Source: Company, JM Financial

Exhibit 11. Steady volumes drove Bollywood growth



INVESTOR UPDATE: Q1 FY'26

Life time Box Office collections have been considered

(2) Source: Ormax Media, Sacnilk, Company estimates

Source: Company, JM Financial

Exhibit 12. Franchise titles fuelled Hollywood’s performance




Exhibit 14. Strong content line-up in FY26. Good mix of Hollywood and Bollywood movies.
Upcoming Movie Pipeline – FY26

	Language	Movie	Key date	Release Date
Q2FY25	English	Nobody 2		22/Aug/25
	English	The Conjuring : Last Rites (IMAX)		5/Sep/25
	English	SAW XI		26/Sep/25
	Hindi	War 2	Independence Day	14/Aug/25
	Hindi	Baaghi 4		5/Sep/25
	Hindi	The Bengal Files		5/Sep/25
	Hindi	Jolly LLB 3		19/Sep/25
	Regional	Coolie - Tamil	Independence Day	14/Aug/25
	Regional	Mass Jataara - Telugu		27/Aug/25
	Regional	Madharasi - Tamil		5/Sep/25
	Regional	Mirai - Telugu		5/Sep/25
	Regional	Nikaa Zaildar 4 - Punjabi		12/Sep/25
	Regional	Akhanda 2		25/Sep/25
Q3FY25	English	Tron: Ares (IMAX)		10/Oct/25
	English	The Black Phone 2		17/Oct/25
	English	Mortal Kombat 2 (IMAX)	Diwali 2025	24/Oct/25
	English	Predator: Badlands		7/Nov/25
	English	The Running Man (4DX)		7/Nov/25
	English	Now You See Me: Now You Don't		14/Nov/25
	English	SISU II		21/Nov/25
	English	Wicked: For Good (IMAX)		21/Nov/25
	English	Zootopia 2 (IMAX)		28/Nov/25
	English	Avatar: Fire and Ash (3D)		19/Dec/25
	English	The Anaconda	Christmas	25/Dec/25
	Hindia	Ek Deewane ki Deewaniyat	Gandhi Jayanti	2/Oct/25
	Hindi	Sunny Sanskari ki Tulsi Kumari	Gandhi Jayanti	2/Oct/25
	Hindi	Ikkis	Gandhi Jayanti	2/Oct/25
	Hindi	Thama	Diwali 2025	24/Oct/25
	Hindi	De De Pyaar De 2		14/Nov/25
	Hindi	120 Bahadur		21/Nov/25
	Hindi	Tere Ishq Mein		28/Nov/25
	Hindi	Arjun Ustara		5/Dec/25
	Hindi	Dhurandhar		5/Dec/25
	Hindi	Alpha	Christmas	25/Dec/25
	Regional	Idli Kadai - Tamil		1/Oct/25
	Regional	Kantara: A Legend Chapter 1 - Kannada	Gandhi Jayanti	2/Oct/25
	Regional	The Raja Saab - Telugu		5/Dec/25
Q1FY26	English	Scream 7		27/Feb/26
	English	Street Fighter		20/Mar/26
	English	Project Hail Mary		20/Mar/26
	Hindi	Border 2		23/Jan/26
	Hindi	Tu Meri Main Tera, Main Tera Tu Meri		13/Feb/26
	Hindi	Mardaani 3		27/Feb/26
	Hindi	Dhamaal 4		20/Mar/26
	Hindi	Love and War		20/Mar/26
	Regional	Jana Nayagan - Tamil		9/Jan/26
	Regional	Toxic - Kannada		19/Mar/26
	Regional	Peddi - Telugu		1/Mar/26

Source: Company, JM Financial

Financial Tables (Consolidated)

Income Statement (INR mn)					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Sales	60,540	57,221	69,216	75,576	77,986
Sales Growth	67.7%	-5.8%	21.0%	9.2%	3.2%
Other Operating Income	531	578	677	719	2,226
Total Revenue	61,071	57,799	69,893	76,295	80,212
Cost of Goods Sold/Op. Exp	19,107	16,454	19,878	22,073	23,396
Personnel Cost	6,573	6,860	7,121	7,436	7,916
Other Expenses	17,290	19,069	21,592	23,179	24,316
EBITDA	18,101	15,416	21,302	23,607	24,584
EBITDA Margin	29.6%	26.7%	30.5%	30.9%	30.6%
EBITDA Growth	72.8%	-14.8%	38.2%	10.8%	4.1%
Depn. & Amort.	12,193	12,798	10,964	10,996	10,978
EBIT	5,908	2,618	10,338	12,611	13,607
Other Income	1,566	1,737	1,470	850	1,053
Finance Cost	7,913	8,095	7,777	7,954	7,739
PBT before Excep. & Forex	-439	-3,740	4,030	5,507	6,921
Excep. & Forex Inc./Loss(-)	0	0	0	0	0
PBT	-439	-3,740	4,030	5,507	6,921
Taxes	-112	-934	1,237	1,377	1,730
Extraordinary Inc./Loss(-)	0	-3	0	0	0
Assoc. Profit/Min. Int.(-)	-7	-13	26	38	48
Reported Net Profit	-320	-2,796	2,768	4,092	5,142
Adjusted Net Profit	-320	-2,794	2,768	4,092	5,142
Net Margin	-0.5%	-4.8%	4.0%	5.4%	6.4%
Diluted Share Cap. (mn)	97.4	97.4	97.4	97.4	97.4
Diluted EPS (INR)	-3.3	-28.7	28.4	42.0	52.8
Diluted EPS Growth	0.0%	0.0%	0.0%	47.8%	25.7%
Total Dividend + Tax	0	0	415	716	1,028
Dividend Per Share (INR)	0.0	0.0	4.3	7.4	10.6

Source: Company, JM Financial

Cash Flow Statement (INR mn)					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Profit before Tax	-439	-3,740	4,030	5,507	6,921
Depn. & Amort.	12,193	12,798	10,964	10,996	10,978
Net Interest Exp. / Inc. (-)	6,347	6,358	6,307	7,104	6,686
Inc (-) / Dec in WCap.	890	3,398	2,245	-59	-713
Others	826	916	0	0	0
Taxes Paid	-27	-62	-1,237	-1,377	-1,730
Operating Cash Flow	19,790	19,668	22,311	22,171	22,141
Capex	-6,344	-3,335	-4,342	-3,638	-3,599
Free Cash Flow	13,446	16,333	17,969	18,533	18,542
Inc (-) / Dec in Investments	-161	174	0	0	0
Others	239	135	1,470	850	1,053
Investing Cash Flow	-6,266	-3,026	-2,872	-2,788	-2,546
Inc / Dec (-) in Capital	188	32	0	0	0
Dividend + Tax thereon	0	0	0	-415	-716
Inc / Dec (-) in Loans	-732	-2,281	-1,118	-689	-655
Others	-12,381	-13,098	-16,071	-14,564	-15,349
Financing Cash Flow	-12,925	-15,347	-17,189	-15,669	-16,720
Inc / Dec (-) in Cash	599	1,295	2,249	3,715	2,875
Opening Cash Balance	3,331	3,930	5,225	9,448	13,163
Closing Cash Balance	3,930	5,225	7,474	13,163	16,038

Source: Company, JM Financial

Balance Sheet (INR mn)					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Shareholders' Fund	73,235	70,514	73,282	76,959	81,385
Share Capital	981	981	981	981	981
Reserves & Surplus	72,254	69,533	72,301	75,978	80,404
Preference Share Capital	0	0	0	0	0
Minority Interest	-3	19	45	83	131
Total Loans	17,177	14,908	13,790	13,100	12,445
Def. Tax Liab. / Assets (-)	-4,881	-5,882	-5,882	-5,882	-5,882
Total - Equity & Liab.	85,528	79,559	81,235	84,260	88,080
Net Fixed Assets	1,47,245	1,40,019	1,39,393	1,37,304	1,35,618
Gross Fixed Assets	1,09,835	1,14,855	1,19,197	1,22,835	1,26,433
Intangible Assets	54,917	49,923	49,537	48,070	47,153
Less: Depn. & Amort.	19,971	25,716	30,298	34,557	38,925
Capital WIP	2,464	957	957	957	957
Investments	161	12	12	12	12
Current Assets	15,890	16,699	22,478	27,688	31,806
Inventories	725	802	895	977	1,008
Sundry Debtors	2,346	2,430	2,939	3,209	3,312
Cash & Bank Balances	3,930	5,225	9,448	13,163	16,038
Loans & Advances	5,578	5,339	5,957	6,802	7,799
Other Current Assets	3,311	2,903	3,239	3,537	3,649
Current Liab. & Prov.	77,768	77,170	80,648	80,744	79,357
Current Liabilities	77,168	76,636	78,334	78,327	76,784
Provisions & Others	600	534	2,314	2,417	2,573
Net Current Assets	-61,878	-60,471	-58,170	-53,056	-47,550
Total - Assets	85,528	79,560	81,235	84,260	88,080

Source: Company, JM Financial

Dupont Analysis					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
Net Margin	-0.5%	-4.8%	4.0%	5.4%	6.4%
Asset Turnover (x)	0.4	0.4	0.5	0.5	0.5
Leverage Factor (x)	2.1	2.1	2.1	2.0	1.9
RoE	-0.4%	-3.9%	3.9%	5.4%	6.5%


Key Ratios					
Y/E March	FY24A	FY25A	FY26E	FY27E	FY28E
BV/Share (INR)	751.8	723.8	752.3	790.0	835.4
ROIC	5.1%	2.4%	9.1%	12.2%	13.2%
ROE	-0.4%	-3.9%	3.9%	5.4%	6.5%
Net Debt/Equity (x)	0.2	0.1	0.1	0.0	0.0
P/E (x)	-315.4	-36.1	36.5	24.7	19.6
P/B (x)	1.4	1.4	1.4	1.3	1.2
EV/EBITDA (x)	16.0	29.5	12.0	9.6	9.2
EV/Sales (x)	1.9	1.9	1.5	1.3	1.2
Debtor days	14	15	15	15	15
Inventory days	4	5	5	5	5
Creditor days	96	119	119	119	115

Note: EV/EBITDA ratio calculated using Pre-Ind AS EBITDA. Source: Company, JM Financial

History of Recommendation and Target Price

Date	Recommendation	Target Price	% Chg.
24-Aug-23	Buy	2,270	
20-Oct-23	Buy	2,340	3.1
4-Dec-23	Buy	2,340	0.0
1-Feb-24	Buy	2,250	-3.8
15-May-24	Buy	2,070	-8.0
23-Jul-24	Buy	2,040	-1.4
15-Oct-24	Buy	1,980	-2.9
15-Jan-25	Buy	1,600	-19.2
7-Feb-25	Buy	1,610	0.6
11-Mar-25	Buy	1,610	0.0
12-May-25	Buy	1,510	-6.2

Recommendation History



APPENDIX I

JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd. and National Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst - INH000000610

Registered Office: 7th Floor, Energy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.

Board: +91 22 6630 3030 | Fax: +91 22 6630 3488 | Email: jmfinancial.research@jmfl.com | www.jmfl.com

Compliance Officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1743 | Email: sahil.salastekar@jmfl.com

Grievance officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1743 | Email: instcompliance@jmfl.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Definition of ratings	
Rating	Meaning
Buy	Total expected returns of more than 10% for stocks with market capitalisation in excess of INR 200 billion and REITs* and more than 15% for all other stocks, over the next twelve months. Total expected return includes dividend yields.
Hold	Price expected to move in the range of 10% downside to 10% upside from the current market price for stocks with market capitalisation in excess of INR 200 billion and REITs* and in the range of 10% downside to 15% upside from the current market price for all other stocks, over the next twelve months.
Sell	Price expected to move downwards by more than 10% from the current market price over the next twelve months.

* REITs refers to Real Estate Investment Trusts.

Research Analyst(s) Certification

The Research Analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that:

All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and

No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures

This research report has been prepared by JM Financial Institutional Securities Limited (JM Financial Institutional Securities) to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its associates solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of JM Financial Institutional Securities. This report has been prepared independent of the companies covered herein.

JM Financial Institutional Securities is registered with the Securities and Exchange Board of India (SEBI) as a Research Analyst and a Stock Broker having trading memberships of the BSE Ltd. (BSE) and National Stock Exchange of India Ltd. (NSE). No material disciplinary action has been taken by SEBI against JM Financial Institutional Securities in the past two financial years which may impact the investment decision making of the investor. Registration granted by SEBI and certification from the National Institute of Securities Market (NISM) in no way guarantee performance of JM Financial Institutional Securities or provide any assurance of returns to investors.

JM Financial Institutional Securities renders stock broking services primarily to institutional investors and provides the research services to its institutional clients/investors. JM Financial Institutional Securities and its associates are part of a multi-service, integrated investment banking, investment management, brokerage and financing group. JM Financial Institutional Securities and/or its associates might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, broking, financing or any other advisory services to the company(ies) covered herein. JM Financial Institutional Securities and/or its associates might have received during the past twelve months or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services.

JM Financial Institutional Securities and/or its associates, their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) covered under this report or (c) act as an advisor or lender/borrower to, or may have any financial interest in, such company(ies) or (d) considering the nature of business/activities that JM Financial Institutional Securities is engaged in, it may have potential conflict of interest at the time of publication of this report on the subject company(ies).

Neither JM Financial Institutional Securities nor its associates or the Research Analyst(s) named in this report or his/her relatives individually own one per cent or more securities of the company(ies) covered under this report, at the relevant date as specified in the SEBI (Research Analysts) Regulations, 2014.

The Research Analyst(s) principally responsible for the preparation of this research report and their immediate relatives are prohibited from buying or selling debt or equity securities, including but not limited to any option, right, warrant, future, long or short position issued by company(ies) covered under this report. The Research Analyst(s) principally responsible for the preparation of this research report or their immediate relatives (as defined under SEBI (Research Analysts) Regulations, 2014); (a) do not have any financial interest in the company(ies) covered under this report or (b) did not receive any compensation from the company(ies) covered under this report, or from any third party, in connection with this report or (c) do not have any other material conflict of interest at the time of publication of this report. Research Analyst(s) are not serving as an officer, director or employee of the company(ies) covered under this report.

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and JM Financial Institutional Securities does not warrant its accuracy or completeness. JM Financial Institutional Securities may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision.

This research report is based on the fundamental research/analysis conducted by the Research Analyst(s) named herein. Accordingly, this report has been prepared by studying/focusing on the fundamentals of the company(ies) covered in this report and other macro-economic factors. JM Financial Institutional Securities may have also issued or may issue, research reports and/or recommendations based on the technical/quantitative analysis of the company(ies) covered in this report by studying and using charts of the stock's price movement, trading volume and/or other volatility parameters. As a result, the views/recommendations expressed in such technical research reports could be inconsistent or even contrary to the views contained in this report.

The investment discussed or views expressed or recommendations/opinions given herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and JM Financial Institutional Securities reserves the right to make modifications and alterations to this statement as they may deem fit from time to time.

This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction.

This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject JM Financial Institutional Securities and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

Additional disclosure only for U.S. persons: JM Financial Institutional Securities has entered into an agreement with JM Financial Securities, Inc. ("JM Financial Securities"), a U.S. registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") in order to conduct certain business in the United States in reliance on the exemption from U.S. broker-dealer registration provided by Rule 15a-6, promulgated under the U.S. Securities Exchange Act of 1934 (the "Exchange Act"), as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission ("SEC") (together "Rule 15a-6").

This research report is distributed in the United States by JM Financial Securities in compliance with Rule 15a-6, and as a "third party research report" for purposes of FINRA Rule 2241. In compliance with Rule 15a-6(a)(3) this research report is distributed only to "major U.S. institutional investors" as defined in Rule 15a-6 and is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research report and are not a major U.S. institutional investor, you are instructed not to read, rely on, or reproduce the contents hereof, and to destroy this research or return it to JM Financial Institutional Securities or to JM Financial Securities.

This research report is a product of JM Financial Institutional Securities, which is the employer of the research analyst(s) solely responsible for its content. The research analyst(s) preparing this research report is/are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to supervision by a U.S. broker-dealer, or otherwise required to satisfy the regulatory licensing requirements of FINRA and may not be subject to the Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Any U.S. person who is recipient of this report that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, must contact, and deal directly through a U.S. registered representative affiliated with a broker-dealer registered with the SEC and a member of FINRA. In the U.S., JM Financial Institutional Securities has an affiliate, JM Financial Securities, Inc. located at 1325 Avenue of the Americas, 27th Floor, Office No. 2715, New York, New York 10019. Telephone +1 (332) 900 4958 which is registered with the SEC and is a member of FINRA and SIPC.

Additional disclosure only for U.K. persons: Neither JM Financial Institutional Securities nor any of its affiliates is authorised in the United Kingdom (U.K.) by the Financial Conduct Authority. As a result, this report is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the matters to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

Additional disclosure only for Canadian persons: This report is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities described herein in Canada or any province or territory thereof. Under no circumstances is this report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This report is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. If you are located in Canada, this report has been made available to you based on your representation that you are an "accredited investor" as such term is defined in National Instrument 45-106 Prospectus Exemptions and a "permitted client" as such term is defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada nor should it be construed as being tailored to the needs of the recipient. Canadian recipients are advised that JM Financial Securities, Inc., JM Financial Institutional Securities Limited, their affiliates and authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential loss arising from any use of this research report or the information contained herein.